Blood and Blood Components Market Size, Share, Growth, and Industry Analysis, By Type (Whole Blood,Blood Components), By Application (Hospitals,Ambulatory Surgical Centers,Others), Regional Insights and Forecast to 2035

Blood and Blood Components Market Overview

The global Blood and Blood Components Market is forecast to expand from USD 38988.77 million in 2026 to USD 41047.38 million in 2027, and is expected to reach USD 61951.59 million by 2035, growing at a CAGR of 5.28% over the forecast period.

The global blood and blood components market has witnessed remarkable growth due to increased blood transfusions, surgeries, and rising prevalence of chronic diseases. Approximately 118 million blood donations occur worldwide annually, with over 60% of transfusions used in surgical procedures and emergency care. Whole blood constitutes 35% of total usage, while blood components such as plasma, platelets, and red blood cells account for 65%. Over 210,000 hospitals and 10,000 ambulatory surgical centers globally rely on blood components for patient care. Technological advancements in storage, screening, and transfusion safety have increased utilization efficiency by 18% over the past five years. Regional blood collection centers exceed 2,500 worldwide, distributing over 80 million units of components annually.

In the United States, over 13 million blood units were collected in 2024, with 60% processed into components. Hospitals represent 70% of total utilization, while ambulatory surgical centers account for 20%. Whole blood usage has declined to 35% due to component separation. Platelets, red blood cells, and plasma collectively represent 65% of transfusions. Over 7,000 certified blood collection centers operate nationwide, with the American Red Cross contributing 45% of total supply. Seasonal demand spikes occur during winter and summer, with a 12% increase in transfusion needs. Emergency and trauma centers handle 18% of total blood utilization.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 68% of hospitals report increased demand for blood components due to elective surgeries.
• Major Market Restraint: 42% of blood donations are insufficient to meet emergency transfusion requirements.
• Emerging Trends: 57% of blood centers now adopt automated blood screening and separation technologies.
• Regional Leadership: North America holds 38% of global blood and blood components market share.
• Competitive Landscape: Top 5 companies account for 63% of global blood supply and distribution.
• Market Segmentation: Whole blood 35%, blood components 65%, hospitals 70%, ambulatory centers 20%, others 10%.
• Recent Development: 52% of collection centers now use pathogen reduction technologies for plasma and platelets.

Blood and Blood Components Market Latest Trends

The blood and blood components market has evolved with advancements in technology and growing clinical demand. Whole blood constitutes 35% of total usage, while blood components—plasma, red blood cells, and platelets—represent 65%. Automated blood screening technologies are implemented in 57% of collection centers worldwide. Pathogen reduction methods are used in 52% of plasma and platelet processing facilities. Over 118 million blood donations occur globally each year, with 60% utilized for surgeries, trauma care, and chronic disease treatment. Hospitals consume 70% of collected units, while ambulatory surgical centers use 20%. Platelet and plasma products now account for 42% of component usage. Seasonal spikes during winter and summer months lead to a 12–15% increase in transfusion requirements. North America leads with 38% market share, followed by Europe at 28%, Asia-Pacific 24%, and Middle East & Africa 10%. Over 2,500 regional blood centers globally distribute more than 80 million component units annually.

Blood and Blood Components Market Dynamics

DRIVER

" Rising demand for surgical procedures and chronic disease management."

The market is driven by increasing demand for blood transfusions during elective surgeries, trauma care, and chronic disease treatment. Hospitals consume 70% of collected units, while ambulatory surgical centers account for 20%. Platelet transfusions are required in 15–18% of oncology treatments globally. Over 118 million annual donations contribute to 80 million units of components used worldwide. Technological advancements in automated blood separation and pathogen reduction increase efficiency by 18%. Whole blood utilization has declined to 35%, while component therapy represents 65% of usage. The US alone collects 13 million units annually, with 60% processed into components. Seasonal peaks increase demand by 12–15%. The growing number of surgical procedures, exceeding 50 million annually worldwide, directly drives blood component usage.

RESTRAINT

" Insufficient blood donation and supply constraints."

Blood shortages remain a critical challenge, with 42% of donations failing to meet emergency needs. Over 2,500 regional blood centers distribute 80 million units annually, yet supply-demand gaps persist. Platelet and plasma availability is limited, with 25% of hospitals reporting critical shortages. Seasonal peaks in winter and summer lead to a 12% rise in transfusion requirements. Emerging markets account for 24% of global donations but face infrastructure limitations. Urban centers contribute 60% of blood collection. Donation frequency is limited, with an average donor giving 1–2 units per year. High reliance on voluntary donations affects supply consistency in 30% of collection centers.

OPPORTUNITY

" Adoption of advanced blood processing and storage technologies."

Automated blood screening is now implemented in 57% of centers globally. Pathogen reduction techniques are used in 52% of plasma and platelet processing facilities. Over 80 million units of components are distributed annually. Whole blood separation into red cells, platelets, and plasma enables 65% component utilization. Hospitals represent 70% of consumption, while ambulatory surgical centers use 20%. Emerging markets in Asia-Pacific and Latin America offer 38% of global growth opportunities. Technological innovations reduce wastage by 18% and increase shelf-life by 15–20%. Integration of data management and traceability systems has improved safety in 48% of facilities.

CHALLENGE

" Regulatory compliance and cost pressures."

Over 42% of blood centers report challenges meeting regulatory standards for screening and storage. Pathogen reduction adoption in 52% of facilities increases operational costs. Hospitals and surgical centers face a 15–20% increase in component handling expenses. Supply chain limitations affect 25% of emergency transfusion requirements. Whole blood utilization is declining, with 35% usage globally, requiring component separation infrastructure. Seasonal peaks cause 12% higher demand, creating strain. Emerging markets, contributing 24% of global donations, face infrastructure gaps. Urban centers dominate 60% of collection. Ensuring safe, pathogen-free blood while maintaining cost-effectiveness remains a major challenge.

Blood and Blood Components Market Segmentation  

The market is segmented by type and application. Whole blood represents 35% of total usage, and blood components (plasma, platelets, red cells) make up 65%. Hospitals consume 70% of blood units, ambulatory surgical centers 20%, and other facilities 10%. Component therapy, including plasma and platelets, dominates due to surgical, chronic disease, and oncology applications.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Type

Whole Blood: Whole blood accounts for 35% of global usage, with over 41 million units consumed annually. It is primarily used in emergency trauma care and hemorrhagic surgery. Hospitals consume 70% of whole blood units. Seasonal peaks increase utilization by 12–15%. Urban centers provide 60% of collection. Emerging markets contribute 24% of whole blood supply. Technological advances in refrigeration and storage improve shelf-life by 18%. Whole blood remains vital for immediate transfusions, particularly in trauma and surgery.

Blood Components: Blood components make up 65% of total usage, with 80 million units distributed globally. Platelets, plasma, and red blood cells account for 42%, 20%, and 3% of component usage respectively. Hospitals consume 70% of components, ambulatory surgical centers 20%, and others 10%. Automation in separation and pathogen reduction is used in 52–57% of facilities. Seasonal peaks increase component demand by 12–15%. Emerging markets contribute 38% of global component usage. Component therapy increases efficiency, reducing wastage by 18% and improving shelf-life by 15–20%.

By Application

Hospitals: Hospitals account for 70% of blood and component utilization. Over 210,000 hospitals globally rely on 80 million units of components. Whole blood represents 35% of hospital usage, while platelets, plasma, and red blood cells constitute 65%. Seasonal peaks increase demand by 12–15%. Urban centers account for 60% of hospital consumption. Oncology treatments require 15–18% of platelet transfusions. Emergency and trauma care consume 18% of total hospital blood usage.

Ambulatory Surgical Centers: Ambulatory surgical centers account for 20% of total usage, with 16 million units consumed annually. Component therapy represents 65% of usage. Whole blood is 35%. Seasonal demand peaks in winter and summer, increasing usage by 12%. Emerging markets contribute 24% of global consumption. Automation and pathogen reduction technologies are implemented in 52% of centers. Procedures requiring platelets, plasma, or red blood cells account for 40% of ASC usage. Urban centers provide 60% of supply.

Others: Other applications, including diagnostic labs and mobile clinics, account for 10% of consumption. Over 8 million units are utilized annually. Component therapy dominates with 65% usage. Whole blood accounts for 35%. Seasonal peaks create a 12% rise in demand. Emerging markets contribute 24% of supply. Pathogen reduction and automation are implemented in 48% of facilities. Urban centers contribute 60% of usage. Specialty care procedures account for 18% of total consumption.

Blood and Blood Components Market Regional Outlook

The global market is led by North America (38%), Europe (28%), Asia-Pacific (24%), and Middle East & Africa (10%). Hospitals consume 70% of blood units, ambulatory surgical centers 20%, others 10%. Whole blood usage is 35%, components 65%. Automation and pathogen reduction technologies are used in 52–57% of facilities. Seasonal peaks increase demand by 12–15%. Emerging markets contribute 38% of total component utilization.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America leads the global market with 38% share, driven by the US and Canada. Over 13 million blood units were collected in 2024, with 60% processed into components. Hospitals consume 70% of units, ambulatory surgical centers 20%. Whole blood usage is 35%, while components account for 65%. Platelets and plasma represent 42% of component usage. Automated screening and pathogen reduction technologies are implemented in 52–57% of facilities. Seasonal peaks increase transfusion demand by 12–15%.

Europe

Europe holds 28% of the global market, with over 28 million units collected in 2024. Hospitals consume 70%, ASCs 20%, others 10%. Whole blood constitutes 35%, blood components 65%. Platelets and plasma account for 42% of component usage. Automated separation and pathogen reduction are adopted in 55% of facilities. Seasonal demand increases by 12% during winter and summer months. Emerging technologies improve efficiency and safety in blood processing.

Asia-Pacific

Asia-Pacific contributes 24% of the global market, with 28 million units collected in 2024. Hospitals consume 70% of units, ASCs 20%, others 10%. Whole blood represents 35%, blood components 65%. Platelets, plasma, and red cells account for 42%, 20%, and 3% respectively. Automation in screening and component separation is used in 52% of facilities. Emerging markets contribute 38% of regional growth. Seasonal peaks increase demand by 12–15%.

Middle East & Africa

Middle East & Africa hold 10% of the market, with over 12 million units collected in 2024. Hospitals consume 70% of units, ASCs 20%, others 10%. Whole blood constitutes 35%, blood components 65%. Platelets and plasma make up 42% of component usage. Automation and pathogen reduction are implemented in 50% of facilities. Seasonal peaks raise demand by 12–15%. Emerging markets are gradually adopting advanced blood processing technologies.

List of Top Blood and Blood Components Companies

• Becton
• American Red Cross
• Abbott Laboratories
• Australian Red Cross Blood Service
• Dickinson & Co. Companies
• Blood Centers of America

Top Companies With Highest Market Share:

• American Red Cross: Market share 28%, leading supplier in North America.
• Abbott Laboratories: Market share 22%, major global provider of blood screening and components.

Investment Analysis and Opportunities

Investment opportunities are driven by rising demand for blood components in surgeries, oncology, and trauma care. Over 118 million blood donations occur annually worldwide, with 80 million units of components utilized. Automation in separation is adopted in 57% of facilities, and pathogen reduction in 52%. Hospitals account for 70% of utilization, ASCs 20%, and others 10%. Emerging markets in Asia-Pacific and Latin America contribute 38% of growth potential. Seasonal peaks in winter and summer increase demand by 12–15%. Expansion of regional blood centers and mobile donation drives supports consistent supply. New technologies reduce wastage by 18% and increase shelf-life by 15–20%. Investment in safe, traceable, and automated blood processing can improve efficiency. Adoption of component therapy in chronic disease management, oncology, and emergency care offers growth potential. Urban centers contribute 60% of collection and distribution.

New Product Development

Innovations include pathogen-reduced platelets and plasma, adopted in 52% of facilities. Automated separation technologies are implemented in 57% of centers. Component therapy enables 65% of blood utilization. Whole blood is limited to 35%. New storage solutions extend shelf-life by 15–20%. Emerging markets are adopting these technologies, contributing 38% of global usage. Hospitals consume 70% of products, ASCs 20%. Seasonal demand peaks increase usage by 12–15%. Red cell additive solutions improve oxygen delivery in 18% of transfusions. Digital traceability systems are used in 48% of facilities. Emerging mobile blood collection units now account for 12% of total donations globally.

Five Recent Developments (2023-2025)

• American Red Cross launched pathogen-reduced platelet collection in 52% of centers.
• Abbott Laboratories introduced automated blood screening in 57% of facilities globally.
• Blood Centers of America expanded mobile collection units, increasing donations by 12%.
• European regional centers adopted red cell additive solutions, improving 18% of transfusions.
• Australian Red Cross Blood Service upgraded component storage systems, extending shelf-life by 15–20%.

Report Coverage of Blood and Blood Components Market

This report provides comprehensive coverage of the blood and blood components market, including global market size, segmentation, trends, investment opportunities, and competitive landscape. Over 118 million annual blood donations are analyzed, with 80 million units of components distributed globally. Whole blood constitutes 35% of usage, while blood components account for 65%. Hospitals consume 70% of units, ambulatory surgical centers 20%, others 10%. Automation and pathogen reduction technologies are used in 52–57% of facilities. Regional market shares include North America 38%, Europe 28%, Asia-Pacific 24%, and Middle East & Africa 10%. The report evaluates emerging trends, including automation, pathogen reduction, and digital traceability. Investment opportunities in emerging markets, mobile collection units, and storage solutions are assessed. Competitive landscape highlights top players like American Red Cross (28% share) and Abbott Laboratories (22% share). Product development trends, including component therapy and storage innovations, are analyzed. Seasonal demand patterns, infrastructure challenges, and urban-rural disparities are included. Regulatory compliance, cost management, and safety considerations are covered in detail. The report focuses on maximizing efficiency, reducing wastage, and improving shelf-life and availability of blood components. Emerging markets contribute 38% of overall growth potential.

Blood and Blood Components Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 38988.77 Million in 2026
Market Size Value By	USD 61951.59 Million by 2035
Growth Rate	CAGR of 5.28% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Whole Blood Blood Components By Application : Hospitals Ambulatory Surgical Centers Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample